Best for pre-bill review and denial prevention
40/50
2nd of 6
| Capture accuracy | Traceability & auditability | Revenue & denial impact | EHR & deployment | Access & transparency |
|---|---|---|---|---|
| 9/10 | 9/10 | 9/10 | 9/10 | 4/10 |
- Best for
- Hospitals that want a pre-bill AI pass over finished charts — labs, imaging, vitals, meds and notes — to catch missed revenue and denial risk before the claim goes out.
- Limitation
- Acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians.
- Price
- Enterprise, sales-led; no published rate
Dimension-by-dimension rubric criteria for AI CDI and utilization review
- Capture accuracy9/10
Category high: 9/10
How reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives.
- Traceability & auditability9/10
Category high: 10/10
Whether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review.
- Revenue & denial impact9/10
Category high: 9/10
Documented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward externally reported results over vendor claims.
- EHR & deployment9/10
Category high: 10/10
Depth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM.
- Access & transparency4/10
Category high: 8/10
Published pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle.

